Business Insider

NRx Pharmaceuticals Files Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Patients at Immediate Risk of Death from COVID-19 Despite Treatment with ...

RADNOR, Pa., Dec. 29, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has filed a new Breakthrough Therapy Designation (BTD) request with the US Food and Drug ...
clinicaladvisor.com

Aviptadil Not Linked to Improvement in COVID-19 Hypoxemic Respiratory Failure

Credit: Getty Images. The TESICO trial compared IV aviptadil vs placebo and IV remdesivir vs placebo in patients with acute hypoxemic respiratory failure due to COVID-19. Aviptadil did not improve ...
Business Insider

NRx Pharmaceuticals Presents Evidence ZYESAMI™ (aviptadil) Helps Prevent "Cytokine Storm" in Patients with COVID-19

RADNOR, Pa., July 19, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP), will present data at the Disease Control and Prevention Summit on July 21, 2021 at 10: ...
Nasdaq

RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells

- Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) was seen in patients with severe medical comorbidities after three days of treatment with RLF-100 under FDA ...
BGR

This Might Be The Breakthrough Coronavirus Cure We've Been Waiting For

A potential coronavirus cure that can reduce recovery time and prevent COVID-19 complications is now in Phase 2/3 testing. The drug is called RLF-100 or aviptadil, and it also received emergency use ...
Nasdaq

FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure

- Aviptadil is now shown as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung - ...
Delaware County Daily Times

NeuroRx Announces ZyesamiTM (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir

RADNOR, Pa., April 6, 2021 /PRNewswire/ — NeuroRx, Inc. reports today that Aviptadil, to be supplied by NeuroRx, has been identified by the National Institutes of Health (NIH) as one of two drugs ...
Yahoo Finance

Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in ...

GENEVA, SWITZERLAND / ACCESSWIRE / May 26, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF), (OTCQB:RLFTF, RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief ...
The Reporter

NRx Pharmaceuticals Announces First Successful Commercial Formulation for ZYESAMITM (aviptadil), Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication ...

RADNOR, Pa., July 22, 2021 /PRNewswire/ — NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has validated the first commercial formulation of ZYESAMITM (aviptadil) for intravenous use, ...
Monthly Prescribing Reference

Aviptadil Gets Orphan Drug Status for Sarcoidosis

RLF-100 (aviptadil) is an inhaled, synthetic formulation of vasoactive intestinal peptide (VIP) for the treatment of sarcoidosis. The Food and Drug Administration (FDA) has granted Orphan Drug ...
Business Wire

RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells

RADNOR, Pa. & GENEVA--(BUSINESS WIRE)--NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF) “Relief” today announced that RLF-100 (aviptadil) showed rapid recovery from respiratory ...